The complexity of PSA interpretation in clinical practice

Area of Science:

• Urology
• Oncology
• Clinical Chemistry

Background:

• Prostate specific antigen (PSA) is a key biomarker for prostate cancer diagnosis.
• Current PSA reference ranges do not definitively rule in or out cancer.
• Calibration methods significantly influence PSA cut-off values.

Purpose of the Study:

• To highlight the variability in PSA testing and its implications for prostate cancer screening.
• To inform clinicians about potential patient misclassification due to PSA variations.

Main Methods:

• Review of PSA calibration standards (Hybritech vs. WHO).
• Analysis of prostate cancer prevalence in screened populations with varying PSA levels.
• Examination of results from major PSA screening trials (ERSPC, PLCO).
• Assessment of biological variation and external quality assessment data for PSA analysis.

Main Results:

• Significant differences in PSA cut-off values exist based on calibration (e.g., 4 μg/L vs. 3.0/3.1 μg/L).
• Prostate cancer prevalence is notable even in men with PSA < 4 μg/L.
• Major trials show conflicting results on PSA screening benefits (ERSPC: 21% risk reduction for death; PLCO: no benefit).
• Method calibration differences can be as high as 22%; biological variation averages 7.3%.

Conclusions:

• PSA test results are highly dependent on calibration method and subject to biological variation.
• Variations in PSA analysis can lead to patient misclassification.
• Current guidelines do not universally recommend PSA screening due to these uncertainties, except for high-risk individuals.